About SELECT clinical study SELECT (Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity) is a randomised, double-blind, parallel-group, placebo-controlled trial designed to evaluate the efficacy of semaglutide 2.4 mg versus placebo as an adjunct to standard of care for the prevention of major adverse cardiac events (MACE) in people with overweight or obesity and established cardiovascular disease with no prior history of diabetes
For tendon, ligament, or joint injury, injection within two to five centimeters of the affected area is the standard approach
Osbert Fernandez MD, FACOG, FAAFP, Medical Director Austin Marie Jacobus RN, MSN, NP-C, VP Clinical
Red flags in the peptide market The peptide market has attracted a significant volume of unverified suppliers, particularly online
HDL-associated estradiol esters increase macrophage cholesterol efflux and other atheroprotective actions